ImmunityBio, Inc.IBRXEarnings & Financial Report
Nasdaq
NextMar 13, 2026
IBRX Q3 2025 Key Financial Metrics
Revenue
$32.1M
Gross Profit
$31.9M
Operating Profit
$-55.6M
Net Profit
$-67.3M
Gross Margin
99.4%
Operating Margin
-173.5%
Net Margin
-209.8%
YoY Growth
425.1%
EPS
$-0.07
Financial Flow
ImmunityBio, Inc. Q3 2025 Financial Summary
ImmunityBio, Inc. reported revenue of $32.1M for Q3 2025, with a net profit of $-67.3M (-209.8% margin). Cost of goods sold was $177.0K, operating expenses totaled $87.5M.
Key Financial Metrics
| Total Revenue | $32.1M |
|---|---|
| Net Profit | $-67.3M |
| Gross Margin | 99.4% |
| Operating Margin | -173.5% |
| Report Period | Q3 2025 |
ImmunityBio, Inc. Annual Revenue by Year
ImmunityBio, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $14.7M).
| Year | Annual Revenue |
|---|---|
| 2024 | $14.7M |
| 2023 | $622.0K |
| 2022 | $240.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $139000 | $40000 | $1.0M | $6.1M | $7.6M | $16.5M | $26.4M | $32.1M |
| YoY Growth | 90.4% | -88.9% | 2453.7% | 7346.3% | 5333.1% | 41192.5% | 2423.9% | 425.1% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $504.5M | $400.7M | $444.3M | $364.6M | $382.9M | $303.8M | $402.1M | $519.0M |
| Liabilities | $1.09B | $1.09B | $1.14B | $1.11B | $871.1M | $894.2M | $971.9M | $1.04B |
| Equity | $-587.0M | $-692.0M | $-698.4M | $-745.1M | $-489.1M | $-591.4M | $-570.7M | $-524.3M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-115.3M | $-107.0M | $-100.3M | $-98.8M | $-85.1M | $-85.9M | $-79.7M | $-68.9M |